To include your compound in the COVID-19 Resource Center, submit it here.

Naked ambition

How miRagen designed its microRNA molecule for systemic delivery in cancer

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without the addition of a conjugate or vehicle.

On Oct. 13, miRagen reported interim data from a Phase I trial of MRG-106 to treat mycosis fungoides-type cutaneous T cell lymphoma (CTCL). All but one of the 23 patients treated showed improvement in total skin disease measured as the change from baseline in modified Severity Weighted Assessment Tool (mSWAT) score. mSWAT assesses skin

Read the full 969 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE